Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion DealSeeking Alpha • 11/12/23
BioNTech Posts a Profit, While Cutting Its Full-Year COVID Vaccine Sales OutlookInvestopedia • 11/06/23
Tesla, Organigram, BioNTech, Dish, Bumble, FreshPet, Berkshire Hathaway – Stocks on the moveProactive Investors • 11/06/23
BioNTech's stock rallies after it posts surprise Q3 profit and revenue that tops estimatesMarket Watch • 11/06/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioNTech SE - BNTXPRNewsWire • 11/03/23
BioNTech SE (BNTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsPRNewsWire • 10/26/23
Pfizer and BioNTech announce positive data in early trial of flu/COVID combination vaccineMarket Watch • 10/26/23
Pfizer and BioNTech - Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19GlobeNewsWire • 10/26/23
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19Business Wire • 10/26/23
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023GlobeNewsWire • 10/23/23
BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023GlobeNewsWire • 10/23/23
Biotech stocks are in a post-pandemic slump and recovery in 2024 is questionableMarket Watch • 10/20/23